Drug cocktail trial aims to extend lives in liver cancer
NCT ID NCT07321613
Summary
This study looked at whether adding three oral medications (thalidomide, carmofur, and compound mylabris capsules) to a standard liver cancer procedure helps patients live longer. Researchers compared 545 people with advanced liver cancer who received either the standard treatment alone or the standard treatment plus the three-drug combination. The goal was to see if the added medications improved survival and tumor response rates.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CANCER (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, China
Conditions
Explore the condition pages connected to this study.